Novalis Biotech in Rheumafinder Investment

Cresco is proud to announce that it has acted as lead counsel for the investment by Novalis Biotech, an early stage venture capital investor in life sciences, in the start-up Rheumafinder, founded by Nicolaas Fosselle (Chief Executive Officer), Dr. Thomas Van Den Berghe (Chief Medical Officer) and Professor Dr. Lennart Jans (Chief Science Officer).

Rheumafinder is a promising start-up developing an AI-powered application that detects signs of rheumatic diseases on a range of radiological imaging modalities. The application analyzes standard medical images requested for any clinical event to detect early signs of structural damage in joints. This early detection tool serves as an invaluable aid to radiologists and rheumatologists, contributing to sustainable healthcare practices by addressing the unmet clinical need of late- and underdiagnosis for rheumatic diseases.

The deal team consisted of Glenn L’hoëst and Dominik Verbist.

More information on this transaction and Rheumafinder’s technology and activities can be found in this article and on the website of Rheumafinder.

For any further information or questions, please contact Glenn L’hoëst.